Now showing items 1-1 of 1

    • Clinical activity of nivolumab in patients with non-clear cell renal cell carcinoma. 

      Appleman, Leonard J; Atkins, Michael B; Barata, Pedro C; Garcia, Jorge A; George, Daniel J; Gilligan, Timothy; Grivas, Petros; ... (15 authors) (Journal for immunotherapy of cancer, 2018-01-29)
      Nivolumab is approved for patients with metastatic renal cell carcinoma (mRCC) refractory to prior antiangiogenic therapy. The clinical activity of nivolumab in patients with non-clear cell RCC subtypes remains unknown as ...